8-K: Aethlon Medical Warrants Fully Exercised

Sentiment:

Capital Structure Update 17 March 2026 9:15 AM

Aethlon Medical, Inc. announced that all previously outstanding pre-funded warrants have been exercised, resulting in 1,569,110 shares of common stock outstanding.

Capital raiseThe exercise of pre-funded warrants represents a form of capital raise, as it typically involves the payment of an exercise price to the company.All previously outstanding pre-funded warrants have now been exercised, completing this phase of capital conversion.

Summary

All previously outstanding pre-funded warrants of Aethlon Medical, Inc. have been exercised.
The company now has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the full exercise of pre-funded warrants simplifies the capital structure and removes potential future overhang, despite the immediate dilution.

Positives

Elimination of potential future dilution from the specific pre-funded warrants.
Simplification of the company's capital structure by removing the warrant overhang.

Negatives

Immediate dilution for existing shareholders due to the issuance of new shares upon warrant exercise.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Management Comments

James B. Frakes, Chief Executive Officer and Chief Financial Officer, signed the report on behalf of Aethlon Medical, Inc.

Industry Context

StockSavvy.ai notes that warrant exercises are a standard mechanism for companies to raise capital and for investors to convert their rights into equity. The full exercise of pre-funded warrants can be viewed as a positive step towards simplifying a company's capital structure, removing uncertainty associated with potential future dilution from these instruments.

Stakeholder Impact

Shareholders: Experience immediate dilution due to the increase in outstanding shares but benefit from the removal of future dilution risk associated with these specific warrants.

Key Dates

Date	Description
March 16, 2026	Date as of which 1,569,110 shares of common stock were outstanding and all previously outstanding pre-funded warrants had been exercised.
March 17, 2026	Date the 8-K report was signed by James B. Frakes.

Recommendation

hold

The full exercise of pre-funded warrants clarifies the company's capital structure and removes future dilution risk from these specific instruments. While it results in immediate dilution, it's a largely administrative event that doesn't fundamentally alter the company's operational outlook, warranting a 'hold' recommendation based solely on this filing.

Keywords

Aethlon Medical, AEMD, warrants, pre-funded warrants, common stock, shares outstanding, dilution, capital structure

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.